Tirzepatide ���子背景与靶点 — Beginner to Advanced

By Editorial Desk · published 2026-01-03 · last reviewed 2026-02-17 · Data

Everything below concerns fatty diacid. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2026-02-17. Numbers and descriptions here follow the published literature rather than marketing material.

Tirzepatide 分子背景与靶点

脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。

该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。

当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。

Background and Molecular Development

Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.

The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.

Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.

Tirzepatide at a glance

Background and Dual Receptor Pharmacology

Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.

Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.

Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.

Related pages on this site

• Quality index
• Lightweight workbook
• Regional report
• Scheduled notes
• Optimized dataset
• Scheduled notes
• Optimized analysis
• Professional toolkit

Molecular Basis and Receptor Pharmacology

Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.

At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.

An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.

Dual Incretin Receptor Agonism

Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.

The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.

In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.

Background from the literature

In addition, on 6 March 2026, as part of the Ecuador conflict, the United States and Ecuadorian Armed Forces airstriked a single target allegedly belonging to FARC dissidents. The strikes came amid tensions between the United States and Venezuela as Trump steadily increased pressure. Venezuela's Nicolás Maduro repeatedly accused the US of seeking regime change which some third-party sources agree with. Some experts, human rights groups and international bodies have said the killings are illegal under US and international law, and the Colombian and Venezuelan governments have accused the US of extrajudicial murder. In 2025 the Republican-controlled US Senate twice rejected resolutions that would limit Trump's authority to continue military action against Venezuela or airstrikes against alleged drug vessels. On 3 January 2026, Maduro was captured and flown out of the country by US forces.

=== Indications === The α-bungarotoxin is among the most well-characterized snake toxins, with its high affinity and specificity for nicotinic acetylcholine receptors. It is a competitive antagonist at nAChR, where it irreversibly and competitively blocks the receptor at the acetylcholine binding sites. It binds to the α1 subunit contained in muscle nAChRs, as well as subsets of neuronal nAChRs like α7-α10. In addition, it was shown that α-bungarotoxin binds to, and block, a subset of GABAA receptors where the β3 subunits connect with each other. With this knowledge in mind, researchers can use α-bungarotoxin as an experimental tool for studying the properties of cholinergic receptors. In addition, by knowing the different and specific binding sites, researchers are able to visualize and track receptor localization and dynamics within cells. This technique has been shown to be easy with the use of a 13-amino acid (WRYYESSLEPYPD) mimotope, which forms a high affinity α-bungarotoxin binding site with the receptors. It has been extensively used in research to study the localization and distribution of these receptors. Through techniques like fluorophore or enzyme conjugation followed by microscopy or immunohistochemical staining, respectively, could give insights about the complex organization and function of the nervous system. With the mentioned techniques, researchers can work towardards a drug development, and understand the disease mechanism. They can idenitify potential drug targets by selectively regulating the activity of certain receptors.

=== Seizures by authorities === Authorities in Latvia and Lithuania reported seizing Carfentanil as an illicit drug in the early 2000s. Around 2016, the United States and Canada reported a dramatic increase in shipment of carfentanil and other strong opioid drugs to customers in North America from Chinese chemical supply firms. In June 2016, the Royal Canadian Mounted Police seized one kilogram of carfentanil shipped from China in a box labeled "printer accessories". According to the Canada Border Services Agency, the shipment contained 50 million potentially lethal doses of the drug, in containers labeled as toner cartridges for HP LaserJet printers. Carfentanil was not a controlled substance in China until 1 March 2017, and until then was manufactured legally and sold openly over the Internet, being actively marketed by several Chinese chemical companies.

Sources: en.wikipedia.org

Further detail

=== Andrey Lyapchev's cabinet === At the end of 1925 Kimon Georgiev actively participated in the events that led to the fall of Aleksander Tsankov. He was one of the activists of the People's Congress who at that time advocated changes in the cabinet, and was charged by the leadership of the Democratic Congress to present its decision in this direction to Tsankov. Discussed as a possible interior minister in a new cabinet, on 4 January 1926 he became Minister of Railways, Posts and Telegraphs in Andrey Lyapchev's first cabinet. After leaving the cabinet, Georgiev was among the members of the internal opposition in the Sgora, grouped around the newspaper "Luch" edited by Petar Todorov, which is why its representatives are often called racists. They advocate stronger state intervention in the economy, limiting partisan appointments in the administration and active action against IMRO. In response, Lyapchev made some concessions, such as the removal of war minister Ivan Valkov. A split occurred within the Radiationist group itself in 1930, when three of its members, including Aleksander Tsankov, were given cabinet seats, and the more extreme opponents, led by Kimon Georgiev, continued to criticize the government. In September, Georgiev himself sharply attacked the war minister in parliament over the Spy Affair. In November, a final rift between the two groups occurred, with the extreme opposition increasingly distancing itself from the Democratic Alliance, consolidating around the Political Circle "Zveno".

De emerges, in retrospect, as a modest self-effacing scientist driven by inner compulsions to grapple with a major scientific problem of the time. His choice of cholera as his field of interest was remarkably appropriate to his setting. To this problem De brought a wonderfully thoughtful approach, together with deep intuition, enabling him to make the long-awaited breakthrough in the field."

=== Suppressing information on health effects === Since the 1970s, DuPont and 3M were aware that PFAS was "highly toxic when inhaled and moderately toxic when ingested". Producers used several strategies to influence science and regulation – most notably, suppressing unfavorable research and distorting public discourse. In 2018, under the first presidency of Donald Trump, White House staff and the EPA pressured the U.S. Agency for Toxic Substances and Disease Registry to suppress a study that showed PFAS to be more dangerous than previously thought.

=== Alternative splicing === There appear to be four isoforms due to splicing. Two of those are truncated on the 3' end of the protein from 266aa and 396aa. Additional location of alternative splice sites are from 79aa to 102aa and 246aa to 260aa.

Sources: en.wikipedia.org

Background from the literature

=== Enzyme production === A significant milestone in the use of K. phaffii in food technology was its GRAS classification by the US Food and Drug Administration, alongside their approval of recombinant proteins. It is now used to produce various enzymes that serve as processing aids and food additives. In bakery production, enzymes produced by genetically modified Komagataella can maintain bread freshness and compensate for variations in flour and malt quality. In brewing, they can reduce beer's alcohol content or modify the flavour and filtration properties of wine. Recombinant expressed phospholipase C is used to degum high-phosphorus vegetable oils by hydrolysing phospholipids. In animal feed, phytase produced by K. phaffii breaks down phytic acid, an antinutrient. Recently, K. phaffii has been used increasingly to produce soy leghemoglobin, a plant heme protein that gives plant-based meat analogues their colour and flavour. This expands the industrial application of K. phaffii from technical enzymes towards functional food ingredients. For this purpose, the yeast utilises its strong methanol-inducible promoters and efficient secretion to produce functional leghemoglobin for use as a food ingredient. Through strain engineering, including optimisation of heme biosynthesis and signal peptides, and controlled fed-batch fermentation, gram-per-litre titres of secreted leghemoglobin have been achieved. This makes large-scale production for meat analogues economically viable.

==== Treatment ==== Food should be offered at the first signs of possible hypoglycemia. If the animal refuses it, a sugar solution (corn syrup, honey, pancake syrup, etc.) should be poured on the finger and rubbed on its gums or under the tongue (sublingually). The solution must be applied this way to prevent possible aspiration of it. Intervet suggests one tablespoon of a sugar solution rubbed onto the gums, regardless of the size of the dog. Another hypoglycemia formula is 1 gram of glucose for every kilogram (2.2 lb) of the animal's body weight. Since sugar acts quickly, a response should be seen within a minute or two. Honey, syrup, or sugar, as simple carbohydrates, act rapidly and will make the blood glucose rise, but the rise will not last very long, as they are broken down quickly by the body. Feeding something containing complex carbohydrates when the pet is able to eat will make sure another hypoglycemia event does not overtake the rapid rise in blood glucose levels from the sugar solution. Complex carbohydrates take longer to be broken down by the body, so they do not raise blood glucose levels until some time after being eaten. A small meal should be fed and the animal taken for medical evaluation to determine if further treatment is needed. Treatment of a serious hypoglycemia episode is similar to that of diabetic humans: using glucose or glucagon infusions, depending on severity. A part from the medicinal way, lifestyle management of the dog can also be considered when preventing a diabetes attack on the dog.

The four substrates of this enzyme are 1-hydroxy-2-naphthoic acid, reduced nicotinamide adenine dinucleotide (NADH), oxygen, and a proton. Its products are 1,2-naphthalenediol, oxidised NAD+, water, and carbon dioxide. It is involved in chrysene degradation in some bacteria.

Sources: en.wikipedia.org

Frequently asked questions